CN105255858B - 一种变换核酸基因型的方法 - Google Patents
一种变换核酸基因型的方法 Download PDFInfo
- Publication number
- CN105255858B CN105255858B CN201510684160.7A CN201510684160A CN105255858B CN 105255858 B CN105255858 B CN 105255858B CN 201510684160 A CN201510684160 A CN 201510684160A CN 105255858 B CN105255858 B CN 105255858B
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- genotype
- fragment
- wild
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 80
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 42
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000001131 transforming effect Effects 0.000 title claims abstract description 7
- 239000012634 fragment Substances 0.000 claims abstract description 123
- 238000006243 chemical reaction Methods 0.000 claims abstract description 85
- 108700028369 Alleles Proteins 0.000 claims abstract description 11
- 238000013467 fragmentation Methods 0.000 claims abstract description 6
- 238000006062 fragmentation reaction Methods 0.000 claims abstract description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 19
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 19
- 108010042407 Endonucleases Proteins 0.000 claims description 16
- 102000004533 Endonucleases Human genes 0.000 claims description 16
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 7
- 238000003205 genotyping method Methods 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 52
- 238000004451 qualitative analysis Methods 0.000 abstract description 3
- 238000004445 quantitative analysis Methods 0.000 abstract description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 87
- 239000000047 product Substances 0.000 description 70
- 238000001962 electrophoresis Methods 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- 230000029087 digestion Effects 0.000 description 24
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 22
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 22
- 101710163270 Nuclease Proteins 0.000 description 19
- 108091008146 restriction endonucleases Proteins 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 238000012163 sequencing technique Methods 0.000 description 18
- 230000035772 mutation Effects 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 13
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 13
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000000246 agarose gel electrophoresis Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 238000012257 pre-denaturation Methods 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108700001666 APC Genes Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 102100021786 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Human genes 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 101000616698 Homo sapiens CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Proteins 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 101000836297 Haemophilus aegyptius Type II restriction enzyme HaeIII Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 101150083915 cdh1 gene Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 2
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 101150080074 TP53 gene Proteins 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150050863 T gene Proteins 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510684160.7A CN105255858B (zh) | 2015-10-20 | 2015-10-20 | 一种变换核酸基因型的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510684160.7A CN105255858B (zh) | 2015-10-20 | 2015-10-20 | 一种变换核酸基因型的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105255858A CN105255858A (zh) | 2016-01-20 |
CN105255858B true CN105255858B (zh) | 2020-03-31 |
Family
ID=55095788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510684160.7A Active CN105255858B (zh) | 2015-10-20 | 2015-10-20 | 一种变换核酸基因型的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105255858B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109880891B (zh) * | 2019-04-22 | 2021-07-30 | 上海交通大学 | 基于核酸酶偶联pcr原理富集低丰度dna突变的检测技术体系及应用 |
CN111876472B (zh) * | 2020-06-17 | 2023-12-01 | 江门市灿明生物科技有限公司 | 多种混合核酸中检测痕量核酸的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20096371A0 (fi) * | 2009-12-21 | 2009-12-21 | Turun Yliopisto | Mutageneesi menetelmä |
CN104120178B (zh) * | 2014-07-03 | 2016-04-20 | 陕西佰美基因股份有限公司 | 一种基于荧光pcr技术检测esr1基因突变的方法 |
-
2015
- 2015-10-20 CN CN201510684160.7A patent/CN105255858B/zh active Active
Non-Patent Citations (1)
Title |
---|
A real-time polymerase chain reaction assay for quantification of allele ratios and correction of amplification bias;Weber M et al;《Analytical Biochemistry》;20030915;第320卷(第2期);摘要、第253页"Materials and methods",第254页 "Results and discussion",图1-3 * |
Also Published As
Publication number | Publication date |
---|---|
CN105255858A (zh) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107488710B (zh) | 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒 | |
US6287825B1 (en) | Methods for reducing the complexity of DNA sequences | |
US10968447B2 (en) | Methods and compositions for enrichment of target polynucleotides | |
RU2603265C2 (ru) | Высокопроизводительный анализ трансгенных границ | |
US20230056763A1 (en) | Methods of targeted sequencing | |
US20240209427A1 (en) | Rare nucleic acid detection | |
JP2012510810A (ja) | アダプター連結制限断片における反復配列を減少させる方法 | |
US20230287477A1 (en) | Methods and compositions for recombinase-mediated selective cleavage of nucleic acids | |
CN105255858B (zh) | 一种变换核酸基因型的方法 | |
JP2023506631A (ja) | 共有結合で閉端された核酸分子末端を使用したngsライブラリー調製 | |
CN116083541B (zh) | 一种富集低丰度单核苷酸变异体的方法 | |
US20230357854A1 (en) | Enhanced sequencing following random dna ligation and repeat element amplification | |
WO2018053070A1 (en) | Improved methods for analyzing edited dna | |
CA2962254C (en) | Composition and method for processing dna | |
US20240182951A1 (en) | Methods for targeted nucleic acid sequencing | |
US20230122979A1 (en) | Methods of sample normalization | |
US20220145359A1 (en) | Methods for targeted depletion of nucleic acids | |
WO2022256926A1 (en) | Detecting a dinucleotide sequence in a target polynucleotide | |
CN116064745A (zh) | 一种5’瓣状核酸酶介导的等温扩增方法 | |
KR101306988B1 (ko) | 다중 타겟 위치의 단일 핵산서열로의 어셈블리 방법 | |
WO2005038026A1 (ja) | 変異のタイピング方法 | |
JP2006121966A (ja) | Hsrda法を用いた特異的dna断片検出法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Andi Inventor after: Lu Guangming Inventor after: Li Kai Inventor before: Zhang Andi Inventor before: Li Kai |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180705 Address after: 410000 No. 1101, C2 building, Yu Yuan Garden, 27, Wen Xuan Road, Changsha hi tech Development Zone, Hunan. Applicant after: GENETALKS BIO-TECH (CHANGSHA) Co.,Ltd. Address before: 215163 building 15, Jinfeng Road, science and Technology City, Suzhou High-tech Zone, Jiangsu, China, 15 Applicant before: SUZHOU JIAZHANG BIOTECHNOLOGY CO.,LTD. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190319 Address after: 423000 Luojiajing 102, Beihu District, Chenzhou City, Hunan Province Applicant after: CHENZHOU NO.1 PEOPLE'S Hospital Applicant after: Luo Dixian Address before: 410000 No. 1101, C2 building, Yu Yuan Garden, 27, Wen Xuan Road, Changsha hi tech Development Zone, Hunan. Applicant before: GENETALKS BIO-TECH (CHANGSHA) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231213 Address after: No.89 Taoyuan Road, Nanshan District, Shenzhen, Guangdong 518052 Patentee after: Luo Dixian Address before: 423000 Luojiajing 102, Beihu District, Chenzhou City, Hunan Province Patentee before: CHENZHOU NO.1 PEOPLE'S Hospital Patentee before: Luo Dixian |